{"id": "article-156148_0", "title": "Cangrelor -- Continuing Education Activity", "content": "Cangrelor, a potent intravenous antiplatelet agent, has been approved by the U.S. Food and Drug Administration (FDA) for its use in specific patient populations undergoing percutaneous coronary intervention (PCI). The drug's efficacy in reducing thrombotic events during and after PCI is attributed to its unique mechanism of action, pharmacokinetics, and pharmacodynamics. Although cangrelor is generally well tolerated, healthcare professionals must be aware of the potential adverse drug reactions (ADRs), drug interactions, contraindications, and managing overdose related to cangrelor. This therapeutic review aims to provide an in-depth analysis of cangrelor, encompassing its indications, FDA approval, off-label uses, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs. Moreover, this activity also highlights the crucial role of interprofessional collaboration in enhancing patient outcomes.", "contents": "Cangrelor -- Continuing Education Activity. Cangrelor, a potent intravenous antiplatelet agent, has been approved by the U.S. Food and Drug Administration (FDA) for its use in specific patient populations undergoing percutaneous coronary intervention (PCI). The drug's efficacy in reducing thrombotic events during and after PCI is attributed to its unique mechanism of action, pharmacokinetics, and pharmacodynamics. Although cangrelor is generally well tolerated, healthcare professionals must be aware of the potential adverse drug reactions (ADRs), drug interactions, contraindications, and managing overdose related to cangrelor. This therapeutic review aims to provide an in-depth analysis of cangrelor, encompassing its indications, FDA approval, off-label uses, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs. Moreover, this activity also highlights the crucial role of interprofessional collaboration in enhancing patient outcomes."}
{"id": "article-156148_1", "title": "Cangrelor -- Continuing Education Activity", "content": "Objectives: Identify appropriate indications for cangrelor therapy in patients undergoing percutaneous coronary intervention. Apply evidence-based guidelines and best practices when selecting cangrelor as an antiplatelet therapy option. Assess the potential risks and complications related to cangrelor therapy. Screen patients for contraindications, potential drug interactions, and individual risk factors influencing cangrelor therapy. Access free multiple choice questions on this topic.", "contents": "Cangrelor -- Continuing Education Activity. Objectives: Identify appropriate indications for cangrelor therapy in patients undergoing percutaneous coronary intervention. Apply evidence-based guidelines and best practices when selecting cangrelor as an antiplatelet therapy option. Assess the potential risks and complications related to cangrelor therapy. Screen patients for contraindications, potential drug interactions, and individual risk factors influencing cangrelor therapy. Access free multiple choice questions on this topic."}
{"id": "article-156148_2", "title": "Cangrelor -- Indications", "content": "The U.S. Food and Drug Administration (FDA) approved cangrelor in June 2015, following comprehensive data from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. These trials involved approximately 25,000 patients and demonstrated the drug's remarkable efficacy and use in patient populations undergoing percutaneous coronary intervention (PCI). [1]", "contents": "Cangrelor -- Indications. The U.S. Food and Drug Administration (FDA) approved cangrelor in June 2015, following comprehensive data from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. These trials involved approximately 25,000 patients and demonstrated the drug's remarkable efficacy and use in patient populations undergoing percutaneous coronary intervention (PCI). [1]"}
{"id": "article-156148_3", "title": "Cangrelor -- Indications", "content": "Cangrelor is the only direct parental P2Y 12 receptor inhibitor currently available, with a rapid onset and offset of action\u00a0in contrast to oral P2Y 12 inhibitors such as clopidogrel, prasugrel, and ticagrelor. [2] This drug is primarily used in patients undergoing PCI, a procedure for treating coronary artery disease. [3]", "contents": "Cangrelor -- Indications. Cangrelor is the only direct parental P2Y 12 receptor inhibitor currently available, with a rapid onset and offset of action\u00a0in contrast to oral P2Y 12 inhibitors such as clopidogrel, prasugrel, and ticagrelor. [2] This drug is primarily used in patients undergoing PCI, a procedure for treating coronary artery disease. [3]"}
{"id": "article-156148_4", "title": "Cangrelor -- Indications", "content": "Cangrelor is used as adjunctive antiplatelet therapy\u00a0for patients undergoing PCI to reduce the risk of thrombotic events during and after the procedure. This treatment is especially beneficial for high-risk patients or those not receiving adequate pretreatment with oral antiplatelet agents. [4] The FDA has approved cangrelor for the following indications:", "contents": "Cangrelor -- Indications. Cangrelor is used as adjunctive antiplatelet therapy\u00a0for patients undergoing PCI to reduce the risk of thrombotic events during and after the procedure. This treatment is especially beneficial for high-risk patients or those not receiving adequate pretreatment with oral antiplatelet agents. [4] The FDA has approved cangrelor for the following indications:"}
{"id": "article-156148_5", "title": "Cangrelor -- Indications", "content": "Prevention of periprocedural myocardial infarction (MI). Cangrelor helps mitigate the risk of periprocedural MI, a potentially life-threatening condition, during the PCI procedure. [5] Prevention of stent thrombosis. Cangrelor effectively reduces the incidence of stent thrombosis, defined as a thrombotic occlusion of a coronary stent, thereby helping to prevent further cardiovascular complications. [6] Prevention of repeat coronary revascularization. Cangrelor therapy helps prevent the need for additional coronary revascularization procedures by effectively reducing the occurrence of restenosis (the narrowing again of the treated artery). [7]", "contents": "Cangrelor -- Indications. Prevention of periprocedural myocardial infarction (MI). Cangrelor helps mitigate the risk of periprocedural MI, a potentially life-threatening condition, during the PCI procedure. [5] Prevention of stent thrombosis. Cangrelor effectively reduces the incidence of stent thrombosis, defined as a thrombotic occlusion of a coronary stent, thereby helping to prevent further cardiovascular complications. [6] Prevention of repeat coronary revascularization. Cangrelor therapy helps prevent the need for additional coronary revascularization procedures by effectively reducing the occurrence of restenosis (the narrowing again of the treated artery). [7]"}
{"id": "article-156148_6", "title": "Cangrelor -- Indications", "content": "Clinicians and patients must understand that cangrelor is designed for short-term use exclusively during the PCI procedure and the immediate post-procedural period.\u00a0This drug is not intended for long-term maintenance therapy and should be bridged with oral antiplatelet agents after hospital admission to ensure optimal treatment continuity and patient safety.\u00a0As per the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography & Interventions (ACC/AHA/SCAI) guidelines, intravenous (IV) cangrelor can be\u00a0a viable option for patients undergoing PCI who have not been previously exposed to P2Y 12 inhibitors for\u00a0reducing\u00a0periprocedural ischemic events. [8]", "contents": "Cangrelor -- Indications. Clinicians and patients must understand that cangrelor is designed for short-term use exclusively during the PCI procedure and the immediate post-procedural period.\u00a0This drug is not intended for long-term maintenance therapy and should be bridged with oral antiplatelet agents after hospital admission to ensure optimal treatment continuity and patient safety.\u00a0As per the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography & Interventions (ACC/AHA/SCAI) guidelines, intravenous (IV) cangrelor can be\u00a0a viable option for patients undergoing PCI who have not been previously exposed to P2Y 12 inhibitors for\u00a0reducing\u00a0periprocedural ischemic events. [8]"}
{"id": "article-156148_7", "title": "Cangrelor -- Indications -- Off-Label Use", "content": "In addition to its approved indications, cangrelor is also used as a bridging agent in patients who have recently undergone stent implantation and require cardiac surgery. [9]", "contents": "Cangrelor -- Indications -- Off-Label Use. In addition to its approved indications, cangrelor is also used as a bridging agent in patients who have recently undergone stent implantation and require cardiac surgery. [9]"}
{"id": "article-156148_8", "title": "Cangrelor -- Mechanism of Action", "content": "Cangrelor, a novel nonthienopyridine adenosine triphosphate (ATP) analog, exerts its antiplatelet effects through a specific mechanism of action. This medication functions by inhibiting blood platelet activation and aggregation, ultimately reducing the risk of thrombotic events. The primary mechanisms of action of cangrelor are\u00a0listed below.", "contents": "Cangrelor -- Mechanism of Action. Cangrelor, a novel nonthienopyridine adenosine triphosphate (ATP) analog, exerts its antiplatelet effects through a specific mechanism of action. This medication functions by inhibiting blood platelet activation and aggregation, ultimately reducing the risk of thrombotic events. The primary mechanisms of action of cangrelor are\u00a0listed below."}
{"id": "article-156148_9", "title": "Cangrelor -- Mechanism of Action", "content": "P2Y 12 receptor antagonism: Cangrelor is a reversible antagonist of the P2Y 12 receptor, an essential receptor involved in platelet activation and aggregation. By binding to the P2Y 12 receptor on platelets, cangrelor effectively blocks the binding of adenosine diphosphate (ADP), a potent platelet activator (see Image. Cangrelor Mechanism of Action). This action leads to inhibiting the ADP-mediated signaling pathway and subsequent platelet activation. [10]", "contents": "Cangrelor -- Mechanism of Action. P2Y 12 receptor antagonism: Cangrelor is a reversible antagonist of the P2Y 12 receptor, an essential receptor involved in platelet activation and aggregation. By binding to the P2Y 12 receptor on platelets, cangrelor effectively blocks the binding of adenosine diphosphate (ADP), a potent platelet activator (see Image. Cangrelor Mechanism of Action). This action leads to inhibiting the ADP-mediated signaling pathway and subsequent platelet activation. [10]"}
{"id": "article-156148_10", "title": "Cangrelor -- Mechanism of Action", "content": "Rapid onset and offset of action: Cangrelor exhibits a rapid onset of action, reaching maximum platelet inhibition within minutes of administration. This quick onset\u00a0renders the drug particularly useful in the acute setting of PCI, where immediate platelet inhibition is essential. Moreover, cangrelor's effects are quickly reversible upon discontinuation, leading to a shorter duration of action than other antiplatelet agents. [11]", "contents": "Cangrelor -- Mechanism of Action. Rapid onset and offset of action: Cangrelor exhibits a rapid onset of action, reaching maximum platelet inhibition within minutes of administration. This quick onset\u00a0renders the drug particularly useful in the acute setting of PCI, where immediate platelet inhibition is essential. Moreover, cangrelor's effects are quickly reversible upon discontinuation, leading to a shorter duration of action than other antiplatelet agents. [11]"}
{"id": "article-156148_11", "title": "Cangrelor -- Mechanism of Action", "content": "Platelet inhibition without requiring metabolism: Unlike oral antiplatelet agents, such as clopidogrel or ticagrelor, cangrelor\u00a0does not rely on metabolic activation within the body.\u00a0Cangrelor is administered as an IV infusion directly into the bloodstream, eliminating the need for hepatic metabolism. This unique characteristic of cangrelor\u00a0ensures consistent platelet inhibition without interpatient variability.", "contents": "Cangrelor -- Mechanism of Action. Platelet inhibition without requiring metabolism: Unlike oral antiplatelet agents, such as clopidogrel or ticagrelor, cangrelor\u00a0does not rely on metabolic activation within the body.\u00a0Cangrelor is administered as an IV infusion directly into the bloodstream, eliminating the need for hepatic metabolism. This unique characteristic of cangrelor\u00a0ensures consistent platelet inhibition without interpatient variability."}
{"id": "article-156148_12", "title": "Cangrelor -- Mechanism of Action", "content": "Preservation of vascular function: Cangrelor exhibits selective inhibition of the P2Y 12 receptor on platelets while leaving other ADP receptors unaffected. This selectivity helps preserve endothelial function and maintain the balance between antithrombotic effects and the physiological hemostatic response. In addition, it enables platelet inhibition without compromising the overall integrity of the vascular system.", "contents": "Cangrelor -- Mechanism of Action. Preservation of vascular function: Cangrelor exhibits selective inhibition of the P2Y 12 receptor on platelets while leaving other ADP receptors unaffected. This selectivity helps preserve endothelial function and maintain the balance between antithrombotic effects and the physiological hemostatic response. In addition, it enables platelet inhibition without compromising the overall integrity of the vascular system."}
{"id": "article-156148_13", "title": "Cangrelor -- Mechanism of Action", "content": "In summary, cangrelor is a potent and reversible intravenous P2Y12 inhibitor, which acts directly and has a short duration of action. Cangrelor quickly inhibits platelet function upon administration and restores normal platelet function within\u00a01 hour of discontinuation.", "contents": "Cangrelor -- Mechanism of Action. In summary, cangrelor is a potent and reversible intravenous P2Y12 inhibitor, which acts directly and has a short duration of action. Cangrelor quickly inhibits platelet function upon administration and restores normal platelet function within\u00a01 hour of discontinuation."}
{"id": "article-156148_14", "title": "Cangrelor -- Mechanism of Action", "content": "According to ACC/AHA/SCAI guidelines, cangrelor leads to predictable, rapid, and profound inhibition of platelets. This action makes cangrelor effective in preventing stent thrombosis, especially in patients not pretreated with a P2Y 12 inhibitor. In addition, cangrelor proves beneficial in situations where the absorption of oral medications is inadequate. [8]", "contents": "Cangrelor -- Mechanism of Action. According to ACC/AHA/SCAI guidelines, cangrelor leads to predictable, rapid, and profound inhibition of platelets. This action makes cangrelor effective in preventing stent thrombosis, especially in patients not pretreated with a P2Y 12 inhibitor. In addition, cangrelor proves beneficial in situations where the absorption of oral medications is inadequate. [8]"}
{"id": "article-156148_15", "title": "Cangrelor -- Mechanism of Action", "content": "A meta-analysis of CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX trials provided substantial support for these observations, indicating a decreased incidence of the combined outcome of death, MI, revascularization driven by ischemia, or stent thrombosis within 48 hours with the use of cangrelor compared to clopidogrel. Furthermore, cangrelor exhibited a remarkable 41% reduction in the occurrence of stent thrombosis. Although significant bleeding events were comparable between the two cohorts, there was a higher frequency of minor bleeding in the cangrelor group. [12]", "contents": "Cangrelor -- Mechanism of Action. A meta-analysis of CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX trials provided substantial support for these observations, indicating a decreased incidence of the combined outcome of death, MI, revascularization driven by ischemia, or stent thrombosis within 48 hours with the use of cangrelor compared to clopidogrel. Furthermore, cangrelor exhibited a remarkable 41% reduction in the occurrence of stent thrombosis. Although significant bleeding events were comparable between the two cohorts, there was a higher frequency of minor bleeding in the cangrelor group. [12]"}
{"id": "article-156148_16", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Understanding the pharmacokinetic profile of cangrelor is essential for appropriate dosing, monitoring, and optimizing therapeutic outcomes. The key aspects of the cangrelor's pharmacokinetics are as follows:", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Understanding the pharmacokinetic profile of cangrelor is essential for appropriate dosing, monitoring, and optimizing therapeutic outcomes. The key aspects of the cangrelor's pharmacokinetics are as follows:"}
{"id": "article-156148_17", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Route of administration: Cangrelor is administered intravenously as a continuous infusion. The\u00a0IV route\u00a0enables rapid and predictable drug delivery, ensuring immediate platelet inhibition during and after PCI. [13]", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Route of administration: Cangrelor is administered intravenously as a continuous infusion. The\u00a0IV route\u00a0enables rapid and predictable drug delivery, ensuring immediate platelet inhibition during and after PCI. [13]"}
{"id": "article-156148_18", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: As cangrelor is administered intravenously, it is fully and immediately available in the systemic circulation, bypassing the need for absorption from the gastrointestinal tract, leading to peak plasma concentration within 2 minutes of its administration.", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Absorption: As cangrelor is administered intravenously, it is fully and immediately available in the systemic circulation, bypassing the need for absorption from the gastrointestinal tract, leading to peak plasma concentration within 2 minutes of its administration."}
{"id": "article-156148_19", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: Cangrelor exhibits rapid distribution throughout the bloodstream, facilitated by its high-water solubility and a volume of distribution of 3.9 L. Approximately 97% to 98% of the drug binds to protein. Notably, cangrelor binds extensively to platelets, primarily through the P2Y 12 receptor, enabling it to reach its site of action and exert potent antiplatelet effects.", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Distribution: Cangrelor exhibits rapid distribution throughout the bloodstream, facilitated by its high-water solubility and a volume of distribution of 3.9 L. Approximately 97% to 98% of the drug binds to protein. Notably, cangrelor binds extensively to platelets, primarily through the P2Y 12 receptor, enabling it to reach its site of action and exert potent antiplatelet effects."}
{"id": "article-156148_20", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Cangrelor undergoes primary metabolism through non-enzymatic hydrolysis in the blood plasma via dephosphorylation. This rapid and spontaneous degradation leads to the formation of an inactive metabolite. This metabolism occurs independently of hepatic enzymes and does not involve the cytochrome P450 system.", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Metabolism: Cangrelor undergoes primary metabolism through non-enzymatic hydrolysis in the blood plasma via dephosphorylation. This rapid and spontaneous degradation leads to the formation of an inactive metabolite. This metabolism occurs independently of hepatic enzymes and does not involve the cytochrome P450 system."}
{"id": "article-156148_21", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Cangrelor and its metabolite are primarily eliminated through renal excretion, with a plasma clearance of about 43 L/h. The elimination half-life of cangrelor is relatively short, averaging about 3 to 6 minutes. [14] This short half-life allows rapid drug elimination, rendering it\u00a0suitable for situations\u00a0for prompt platelet inhibition.", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Elimination: Cangrelor and its metabolite are primarily eliminated through renal excretion, with a plasma clearance of about 43 L/h. The elimination half-life of cangrelor is relatively short, averaging about 3 to 6 minutes. [14] This short half-life allows rapid drug elimination, rendering it\u00a0suitable for situations\u00a0for prompt platelet inhibition."}
{"id": "article-156148_22", "title": "Cangrelor -- Mechanism of Action -- Pharmacokinetics", "content": "Clinical implications: The favorable pharmacokinetic profile of cangrelor, characterized by its short half-life and rapid reversibility, holds significant clinical implications. Healthcare professionals can benefit from its predictable and controllable pharmacokinetics, enabling them to adjust and titrate the infusion rate as needed during PCI procedures.", "contents": "Cangrelor -- Mechanism of Action -- Pharmacokinetics. Clinical implications: The favorable pharmacokinetic profile of cangrelor, characterized by its short half-life and rapid reversibility, holds significant clinical implications. Healthcare professionals can benefit from its predictable and controllable pharmacokinetics, enabling them to adjust and titrate the infusion rate as needed during PCI procedures."}
{"id": "article-156148_23", "title": "Cangrelor -- Administration", "content": "Cangrelor is available in a parenteral dosage form, specifically as a lyophilized powder for IV infusion. The lyophilized powder is reconstituted with a suitable diluent to prepare a solution for IV administration.\u00a0Cangrelor is typically supplied in vials or single-use infusion bags.", "contents": "Cangrelor -- Administration. Cangrelor is available in a parenteral dosage form, specifically as a lyophilized powder for IV infusion. The lyophilized powder is reconstituted with a suitable diluent to prepare a solution for IV administration.\u00a0Cangrelor is typically supplied in vials or single-use infusion bags."}
{"id": "article-156148_24", "title": "Cangrelor -- Administration -- Available Dosage Forms", "content": "Cangrelor is available in an IV infusion form.", "contents": "Cangrelor -- Administration -- Available Dosage Forms. Cangrelor is available in an IV infusion form."}
{"id": "article-156148_25", "title": "Cangrelor -- Administration -- Strength", "content": "The available strength of cangrelor is 50 mg per vial.", "contents": "Cangrelor -- Administration -- Strength. The available strength of cangrelor is 50 mg per vial."}
{"id": "article-156148_26", "title": "Cangrelor -- Administration -- Adult Dosage", "content": "Loading dose: A loading dose of cangrelor is usually administered before starting the infusion to ensure a rapid onset of platelet inhibition. The recommended loading dose of cangrelor is 30 mcg/kg, given as a bolus injection over a short duration, such as 1 minute. [15]", "contents": "Cangrelor -- Administration -- Adult Dosage. Loading dose: A loading dose of cangrelor is usually administered before starting the infusion to ensure a rapid onset of platelet inhibition. The recommended loading dose of cangrelor is 30 mcg/kg, given as a bolus injection over a short duration, such as 1 minute. [15]"}
{"id": "article-156148_27", "title": "Cangrelor -- Administration -- Adult Dosage", "content": "Continuous infusion: Following the loading dose, a continuous infusion of cangrelor is initiated. The infusion rate is adjusted according to the patient's weight to maintain therapeutic platelet inhibition. The recommended infusion rate of 4 mcg/kg/min allows for a continuous administration of cangrelor throughout the PCI procedure and up to 2 hours after the procedure.", "contents": "Cangrelor -- Administration -- Adult Dosage. Continuous infusion: Following the loading dose, a continuous infusion of cangrelor is initiated. The infusion rate is adjusted according to the patient's weight to maintain therapeutic platelet inhibition. The recommended infusion rate of 4 mcg/kg/min allows for a continuous administration of cangrelor throughout the PCI procedure and up to 2 hours after the procedure."}
{"id": "article-156148_28", "title": "Cangrelor -- Administration -- Adult Dosage", "content": "Adjustment of dosing: The infusion rate of cangrelor can be adjusted based on individual patient factors, such as response to therapy, bleeding risk, and the complexity of the PCI procedure. Dosing may need to be titrated up or down to achieve the desired level of platelet inhibition while carefully managing the risk of bleeding complications.", "contents": "Cangrelor -- Administration -- Adult Dosage. Adjustment of dosing: The infusion rate of cangrelor can be adjusted based on individual patient factors, such as response to therapy, bleeding risk, and the complexity of the PCI procedure. Dosing may need to be titrated up or down to achieve the desired level of platelet inhibition while carefully managing the risk of bleeding complications."}
{"id": "article-156148_29", "title": "Cangrelor -- Administration -- Adult Dosage", "content": "Duration of therapy: Cangrelor therapy is typically limited to the duration of the PCI procedure and the immediate post-procedural period. Upon completion of the PCI procedure, patients are often transitioned to oral antiplatelet agents, such as clopidogrel (600 mg), ticagrelor (180 mg), or prasugrel (60 mg), for long-term maintenance therapy. [16] [17]", "contents": "Cangrelor -- Administration -- Adult Dosage. Duration of therapy: Cangrelor therapy is typically limited to the duration of the PCI procedure and the immediate post-procedural period. Upon completion of the PCI procedure, patients are often transitioned to oral antiplatelet agents, such as clopidogrel (600 mg), ticagrelor (180 mg), or prasugrel (60 mg), for long-term maintenance therapy. [16] [17]"}
{"id": "article-156148_30", "title": "Cangrelor -- Administration -- Specific Patient Population", "content": "Hepatic impairment: Cangrelor has not been specifically studied in patients with hepatic impairment. As the metabolism of cangrelor is not\u00a0dependent on hepatic function, dosage adjustment is not necessary for patients with hepatic impairment. [18]", "contents": "Cangrelor -- Administration -- Specific Patient Population. Hepatic impairment: Cangrelor has not been specifically studied in patients with hepatic impairment. As the metabolism of cangrelor is not\u00a0dependent on hepatic function, dosage adjustment is not necessary for patients with hepatic impairment. [18]"}
{"id": "article-156148_31", "title": "Cangrelor -- Administration -- Specific Patient Population", "content": "Renal impairment: Typically, no dosage adjustment is necessary for patients with mild, moderate, or severe renal impairment when using cangrelor. However, close monitoring for potential adverse effects and platelet inhibition response is strongly recommended.", "contents": "Cangrelor -- Administration -- Specific Patient Population. Renal impairment: Typically, no dosage adjustment is necessary for patients with mild, moderate, or severe renal impairment when using cangrelor. However, close monitoring for potential adverse effects and platelet inhibition response is strongly recommended."}
{"id": "article-156148_32", "title": "Cangrelor -- Administration -- Specific Patient Population", "content": "Pregnancy considerations: Limited clinical data exists regarding the use of cangrelor during pregnancy. In pregnant patients requiring intervention, IV heparin is the preferred anticoagulant. [19] As the safety of cangrelor for both the mother and the developing fetus has not been established, its use during pregnancy should be avoided unless the potential benefits outweigh the risks.", "contents": "Cangrelor -- Administration -- Specific Patient Population. Pregnancy considerations: Limited clinical data exists regarding the use of cangrelor during pregnancy. In pregnant patients requiring intervention, IV heparin is the preferred anticoagulant. [19] As the safety of cangrelor for both the mother and the developing fetus has not been established, its use during pregnancy should be avoided unless the potential benefits outweigh the risks."}
{"id": "article-156148_33", "title": "Cangrelor -- Administration -- Specific Patient Population", "content": "Breastfeeding considerations:\u00a0Limited data exist on the excretion of cangrelor in human milk and its potential effects on breastfed infants. Therefore, caution should be exercised when considering the use of cangrelor during lactation. [18] Pediatric patients:\u00a0The safety and effectiveness of cangrelor have not been established in the pediatric population.", "contents": "Cangrelor -- Administration -- Specific Patient Population. Breastfeeding considerations:\u00a0Limited data exist on the excretion of cangrelor in human milk and its potential effects on breastfed infants. Therefore, caution should be exercised when considering the use of cangrelor during lactation. [18] Pediatric patients:\u00a0The safety and effectiveness of cangrelor have not been established in the pediatric population."}
{"id": "article-156148_34", "title": "Cangrelor -- Administration -- Specific Patient Population", "content": "Geriatric patients: Typically, no dosage adjustment is required for geriatric patients. Patients 75 and older have a higher risk of experiencing moderate-to-severe bleeding, which is approximately 3 times greater than younger patients. However, compared to clopidogrel, cangrelor provides comparable effectiveness in patients both older and younger than\u00a075 without raising the chances of significant bleeding. [20]", "contents": "Cangrelor -- Administration -- Specific Patient Population. Geriatric patients: Typically, no dosage adjustment is required for geriatric patients. Patients 75 and older have a higher risk of experiencing moderate-to-severe bleeding, which is approximately 3 times greater than younger patients. However, compared to clopidogrel, cangrelor provides comparable effectiveness in patients both older and younger than\u00a075 without raising the chances of significant bleeding. [20]"}
{"id": "article-156148_35", "title": "Cangrelor -- Adverse Effects", "content": "Like\u00a0other medications, cangrelor can potentially cause adverse drug reactions (ADRs) in some patients. [21] The following is a list of some common ADRs associated with the use of cangrelor.", "contents": "Cangrelor -- Adverse Effects. Like\u00a0other medications, cangrelor can potentially cause adverse drug reactions (ADRs) in some patients. [21] The following is a list of some common ADRs associated with the use of cangrelor."}
{"id": "article-156148_36", "title": "Cangrelor -- Adverse Effects", "content": "Bleeding: The most common adverse effect of cangrelor is bleeding, ranging from minor events, such as nosebleeds or bruising, to more severe bleeding events. These bleeding events may occur at the site of vascular access, surgical sites, or other locations in the body.", "contents": "Cangrelor -- Adverse Effects. Bleeding: The most common adverse effect of cangrelor is bleeding, ranging from minor events, such as nosebleeds or bruising, to more severe bleeding events. These bleeding events may occur at the site of vascular access, surgical sites, or other locations in the body."}
{"id": "article-156148_37", "title": "Cangrelor -- Adverse Effects", "content": "Thrombocytopenia:\u00a0Cangrelor can lead to thrombocytopenia, which may increase the risk of bleeding. [22]", "contents": "Cangrelor -- Adverse Effects. Thrombocytopenia:\u00a0Cangrelor can lead to thrombocytopenia, which may increase the risk of bleeding. [22]"}
{"id": "article-156148_38", "title": "Cangrelor -- Adverse Effects", "content": "Hypersensitivity reactions: Cangrelor may lead to hypersensitivity or allergic reactions in\u00a0some patients, which may present as skin rash, itching, hives, or swelling.", "contents": "Cangrelor -- Adverse Effects. Hypersensitivity reactions: Cangrelor may lead to hypersensitivity or allergic reactions in\u00a0some patients, which may present as skin rash, itching, hives, or swelling."}
{"id": "article-156148_39", "title": "Cangrelor -- Adverse Effects", "content": "Nausea and vomiting: Cangrelor may cause gastrointestinal symptoms in some patients, such as nausea and vomiting.", "contents": "Cangrelor -- Adverse Effects. Nausea and vomiting: Cangrelor may cause gastrointestinal symptoms in some patients, such as nausea and vomiting."}
{"id": "article-156148_40", "title": "Cangrelor -- Adverse Effects", "content": "Hypotension: Cangrelor can potentially lower the blood pressure in patients, which may lead to hypotension. Therefore,\u00a0healthcare professionals should closely monitor patients' blood pressure during cangrelor administration.", "contents": "Cangrelor -- Adverse Effects. Hypotension: Cangrelor can potentially lower the blood pressure in patients, which may lead to hypotension. Therefore,\u00a0healthcare professionals should closely monitor patients' blood pressure during cangrelor administration."}
{"id": "article-156148_41", "title": "Cangrelor -- Adverse Effects", "content": "Local site reactions: In certain instances, patients may experience local site reactions at the injection or infusion site, including pain, redness, or swelling.", "contents": "Cangrelor -- Adverse Effects. Local site reactions: In certain instances, patients may experience local site reactions at the injection or infusion site, including pain, redness, or swelling."}
{"id": "article-156148_42", "title": "Cangrelor -- Adverse Effects -- Glycoprotein IIb/IIIa Inhibitors", "content": "Cangrelor should not be coadministered with glycoprotein IIb/IIIa inhibitors, such as abciximab, eptifibatide, or tirofiban, as this\u00a0combination may increase bleeding risk. [23]", "contents": "Cangrelor -- Adverse Effects -- Glycoprotein IIb/IIIa Inhibitors. Cangrelor should not be coadministered with glycoprotein IIb/IIIa inhibitors, such as abciximab, eptifibatide, or tirofiban, as this\u00a0combination may increase bleeding risk. [23]"}
{"id": "article-156148_43", "title": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors", "content": "Cangrelor should be used cautiously with other P2Y 12 inhibitors, such as clopidogrel, ticagrelor, and prasugrel. Cangrelor is known for its high P2Y 12 receptor affinity, which prevents other\u00a0P2Y 12 agents from binding to the receptor. Consequently, there is a concern that if additional P2 12 inhibitors are administered during cangrelor infusion, the other drugs (or their metabolites) will be unable to bind to the P2Y 12 receptor, resulting in a lack of antiplatelet effects and ischemic protection. [9] Specific recommendations for switching from IV cangrelor to oral P2Y 12 inhibitors are listed below.", "contents": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors. Cangrelor should be used cautiously with other P2Y 12 inhibitors, such as clopidogrel, ticagrelor, and prasugrel. Cangrelor is known for its high P2Y 12 receptor affinity, which prevents other\u00a0P2Y 12 agents from binding to the receptor. Consequently, there is a concern that if additional P2 12 inhibitors are administered during cangrelor infusion, the other drugs (or their metabolites) will be unable to bind to the P2Y 12 receptor, resulting in a lack of antiplatelet effects and ischemic protection. [9] Specific recommendations for switching from IV cangrelor to oral P2Y 12 inhibitors are listed below."}
{"id": "article-156148_44", "title": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors", "content": "Clopidogrel: During cangrelor infusion, the high receptor occupancy prevents the binding of clopidogrel's active metabolite to the P2Y 12 receptor, leading to a lack of platelet inhibitory effect. Clopidogrel is administered at the end of the cangrelor infusion to avoid this interaction, allowing sufficient time for cangrelor to wash out from the system and subsequent binding of clopidogrel's active metabolite to the\u00a0P2Y 12 receptor. Therefore, it is recommended to administer clopidogrel after the discontinuation of cangrelor infusion to avoid drug interactions. [24]", "contents": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors. Clopidogrel: During cangrelor infusion, the high receptor occupancy prevents the binding of clopidogrel's active metabolite to the P2Y 12 receptor, leading to a lack of platelet inhibitory effect. Clopidogrel is administered at the end of the cangrelor infusion to avoid this interaction, allowing sufficient time for cangrelor to wash out from the system and subsequent binding of clopidogrel's active metabolite to the\u00a0P2Y 12 receptor. Therefore, it is recommended to administer clopidogrel after the discontinuation of cangrelor infusion to avoid drug interactions. [24]"}
{"id": "article-156148_45", "title": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors", "content": "Ticagrelor: Due to its extended systemic half-life and that of its major metabolite, ticagrelor can be safely administered at any time, whether it be before, during, or after cangrelor infusion, without significant drug interactions. A recent clinical trial, known as The Switching Antiplatelet (SWAP)-5 Study, specifically investigated the use of cangrelor in patients pretreated with ticagrelor. Results indicated that administering cangrelor to patients pretreated with ticagrelor enhanced platelet inhibition without any noticeable differences in pharmacokinetic or pharmacodynamic profiles upon discontinuing the drug infusion. Moreover, this study observed no significant drug interactions between cangrelor and ticagrelor. [25]", "contents": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors. Ticagrelor: Due to its extended systemic half-life and that of its major metabolite, ticagrelor can be safely administered at any time, whether it be before, during, or after cangrelor infusion, without significant drug interactions. A recent clinical trial, known as The Switching Antiplatelet (SWAP)-5 Study, specifically investigated the use of cangrelor in patients pretreated with ticagrelor. Results indicated that administering cangrelor to patients pretreated with ticagrelor enhanced platelet inhibition without any noticeable differences in pharmacokinetic or pharmacodynamic profiles upon discontinuing the drug infusion. Moreover, this study observed no significant drug interactions between cangrelor and ticagrelor. [25]"}
{"id": "article-156148_46", "title": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors", "content": "Prasugrel:\u00a0The transition from cangrelor to prasugrel should occur after the infusion discontinues\u00a0to avoid potential drug interactions. For an effective\u00a0transition, initiating the shift approximately 30 minutes before the cangrelor infusion is completed is advisable. [26] International expert consensus recommends early administration of ticagrelor during\u00a0PCI to minimize the potential gap in platelet inhibition during the transition from cangrelor infusion. [27]", "contents": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors. Prasugrel:\u00a0The transition from cangrelor to prasugrel should occur after the infusion discontinues\u00a0to avoid potential drug interactions. For an effective\u00a0transition, initiating the shift approximately 30 minutes before the cangrelor infusion is completed is advisable. [26] International expert consensus recommends early administration of ticagrelor during\u00a0PCI to minimize the potential gap in platelet inhibition during the transition from cangrelor infusion. [27]"}
{"id": "article-156148_47", "title": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors", "content": "In vitro studies have demonstrated that cangrelor does not inhibit the activity of cytochrome P450\u00a0enzymes\u00a0at therapeutic concentrations. Consequently, the administration of cangrelor is not anticipated to interfere with the hepatic metabolism of other concurrently administered therapeutic agents. [28]", "contents": "Cangrelor -- Adverse Effects -- P2Y 12 Inhibitors. In vitro studies have demonstrated that cangrelor does not inhibit the activity of cytochrome P450\u00a0enzymes\u00a0at therapeutic concentrations. Consequently, the administration of cangrelor is not anticipated to interfere with the hepatic metabolism of other concurrently administered therapeutic agents. [28]"}
{"id": "article-156148_48", "title": "Cangrelor -- Adverse Effects -- Thrombolytic Agents", "content": "Cangrelor requires close monitoring and caution when used concomitantly with thrombolytic agents, such as alteplase or reteplase, due to an increased risk of bleeding. [29]", "contents": "Cangrelor -- Adverse Effects -- Thrombolytic Agents. Cangrelor requires close monitoring and caution when used concomitantly with thrombolytic agents, such as alteplase or reteplase, due to an increased risk of bleeding. [29]"}
{"id": "article-156148_49", "title": "Cangrelor -- Adverse Effects -- Abrocitinib", "content": "Cangrelor can potentiate the\u00a0antiplatelet effect of abrocitinib. Therefore, the combination of these medications should be avoided. [30]", "contents": "Cangrelor -- Adverse Effects -- Abrocitinib. Cangrelor can potentiate the\u00a0antiplatelet effect of abrocitinib. Therefore, the combination of these medications should be avoided. [30]"}
{"id": "article-156148_50", "title": "Cangrelor -- Adverse Effects -- Anticoagulants", "content": "The administration of P2Y 12 inhibitors with anticoagulants such as heparin, warfarin, or direct oral anticoagulants may increase the risk of bleeding. Therefore, it is essential to exercise caution when using this combination of medications. [31]", "contents": "Cangrelor -- Adverse Effects -- Anticoagulants. The administration of P2Y 12 inhibitors with anticoagulants such as heparin, warfarin, or direct oral anticoagulants may increase the risk of bleeding. Therefore, it is essential to exercise caution when using this combination of medications. [31]"}
{"id": "article-156148_51", "title": "Cangrelor -- Contraindications", "content": "Cangrelor is contraindicated in individuals with known hypersensitivity or allergic reactions to cangrelor or its components. Cangrelor is contraindicated in cases of active pathological bleeding, including gastrointestinal bleeding or intracranial hemorrhage. [18]", "contents": "Cangrelor -- Contraindications. Cangrelor is contraindicated in individuals with known hypersensitivity or allergic reactions to cangrelor or its components. Cangrelor is contraindicated in cases of active pathological bleeding, including gastrointestinal bleeding or intracranial hemorrhage. [18]"}
{"id": "article-156148_52", "title": "Cangrelor -- Contraindications -- Box Warning", "content": "The FDA has issued no specific boxed warnings for cangrelor. However, it\u00a0is essential to recognize that drug safety information can evolve over time.", "contents": "Cangrelor -- Contraindications -- Box Warning. The FDA has issued no specific boxed warnings for cangrelor. However, it\u00a0is essential to recognize that drug safety information can evolve over time."}
{"id": "article-156148_53", "title": "Cangrelor -- Contraindications -- Precautions", "content": "Bleeding risk: Cangrelor increases the risk of bleeding, which can be severe or even life-threatening. [32] therefore, clinicians should exercise caution when administering cangrelor to patients at an increased risk of bleeding, including those with a recent history of surgery, bleeding disorders, or significant trauma. Close monitoring for signs of bleeding and appropriate management strategies should be implemented to mitigate potential risks and ensure patient safety.", "contents": "Cangrelor -- Contraindications -- Precautions. Bleeding risk: Cangrelor increases the risk of bleeding, which can be severe or even life-threatening. [32] therefore, clinicians should exercise caution when administering cangrelor to patients at an increased risk of bleeding, including those with a recent history of surgery, bleeding disorders, or significant trauma. Close monitoring for signs of bleeding and appropriate management strategies should be implemented to mitigate potential risks and ensure patient safety."}
{"id": "article-156148_54", "title": "Cangrelor -- Contraindications -- Precautions", "content": "Thrombocytopenia: Cangrelor can cause a decrease in platelet count, a condition known as thrombocytopenia. Therefore, regular monitoring of platelet counts is recommended, especially during prolonged use or in patients with risk factors for thrombocytopenia.", "contents": "Cangrelor -- Contraindications -- Precautions. Thrombocytopenia: Cangrelor can cause a decrease in platelet count, a condition known as thrombocytopenia. Therefore, regular monitoring of platelet counts is recommended, especially during prolonged use or in patients with risk factors for thrombocytopenia."}
{"id": "article-156148_55", "title": "Cangrelor -- Contraindications -- Precautions", "content": "Surgical procedures: Cangrelor's antiplatelet effects can prolong bleeding time; therefore, physicians should exercise caution when scheduling surgical procedures. The decision to discontinue cangrelor before surgery should be carefully considered, considering the patient's bleeding risk and the desired duration of the antiplatelet effects.", "contents": "Cangrelor -- Contraindications -- Precautions. Surgical procedures: Cangrelor's antiplatelet effects can prolong bleeding time; therefore, physicians should exercise caution when scheduling surgical procedures. The decision to discontinue cangrelor before surgery should be carefully considered, considering the patient's bleeding risk and the desired duration of the antiplatelet effects."}
{"id": "article-156148_56", "title": "Cangrelor -- Contraindications -- Precautions", "content": "According to the American Society of Regional Anesthesia (ASRA) and Pain Medicine guidelines, the risk of severe bleeding associated with a neuraxial block while the residual effect of cangrelor is present remains unknown. ASRA recommends\u00a0removing neuraxial catheters before reinstituting cangrelor therapy postoperatively. The first postoperative dose of cangrelor should be administered 8 hours after the neuraxial catheter has been removed. [33]", "contents": "Cangrelor -- Contraindications -- Precautions. According to the American Society of Regional Anesthesia (ASRA) and Pain Medicine guidelines, the risk of severe bleeding associated with a neuraxial block while the residual effect of cangrelor is present remains unknown. ASRA recommends\u00a0removing neuraxial catheters before reinstituting cangrelor therapy postoperatively. The first postoperative dose of cangrelor should be administered 8 hours after the neuraxial catheter has been removed. [33]"}
{"id": "article-156148_57", "title": "Cangrelor -- Monitoring", "content": "Patients receiving cangrelor should be closely monitored for signs of bleeding, both visibly and through laboratory testing (complete blood count). An advanced monitoring technique known as the P2Y 12 monitoring assay can also be employed. The P2Y 12 assay estimates the degree of platelet inhibition by P2Y 12 inhibitors, such as cangrelor. The normal reference range for P2Y 12 reaction units (PRUs) is 194 to 418. However, PRU results may be unreliable in patients with altered hematocrit, platelet counts, or fibrinogen levels. Therefore, it is crucial to monitor hematocrit, platelet count, and fibrinogen levels during cangrelor infusion. [34]", "contents": "Cangrelor -- Monitoring. Patients receiving cangrelor should be closely monitored for signs of bleeding, both visibly and through laboratory testing (complete blood count). An advanced monitoring technique known as the P2Y 12 monitoring assay can also be employed. The P2Y 12 assay estimates the degree of platelet inhibition by P2Y 12 inhibitors, such as cangrelor. The normal reference range for P2Y 12 reaction units (PRUs) is 194 to 418. However, PRU results may be unreliable in patients with altered hematocrit, platelet counts, or fibrinogen levels. Therefore, it is crucial to monitor hematocrit, platelet count, and fibrinogen levels during cangrelor infusion. [34]"}
{"id": "article-156148_58", "title": "Cangrelor -- Toxicity", "content": "Severe toxicity related specifically to cangrelor is rare. [35] Nevertheless, some potential toxicity concerns are associated with cangrelor use, including bleeding, allergic reactions, thrombocytopenia, and local site reactions.\u00a0Data on cangrelor overdose were assessed in\u00a0a pooled analysis of the CHAMPION trials. The study identified 36 patients who experienced an overdose of cangrelor. In most cases, the cangrelor dose did not exceed 2.5 times the recommended dosage. Notably, only 1 patient who experienced an overdose had a severe bleeding event. [36]", "contents": "Cangrelor -- Toxicity. Severe toxicity related specifically to cangrelor is rare. [35] Nevertheless, some potential toxicity concerns are associated with cangrelor use, including bleeding, allergic reactions, thrombocytopenia, and local site reactions.\u00a0Data on cangrelor overdose were assessed in\u00a0a pooled analysis of the CHAMPION trials. The study identified 36 patients who experienced an overdose of cangrelor. In most cases, the cangrelor dose did not exceed 2.5 times the recommended dosage. Notably, only 1 patient who experienced an overdose had a severe bleeding event. [36]"}
{"id": "article-156148_59", "title": "Cangrelor -- Toxicity -- Signs and Symptoms of Overdose", "content": "Common signs and symptoms of cangrelor overdose include bleeding and thrombocytopenia.", "contents": "Cangrelor -- Toxicity -- Signs and Symptoms of Overdose. Common signs and symptoms of cangrelor overdose include bleeding and thrombocytopenia."}
{"id": "article-156148_60", "title": "Cangrelor -- Toxicity -- Managing Overdose", "content": "Managing cangrelor overdose involves providing supportive care and closely monitoring the patient's condition as no specific antidote is available for the drug. Stop the cangrelor infusion immediately and seek assistance from a rapid response team. [37] Monitor the patient's vital signs, including blood pressure, heart rate, and oxygen saturation. Perform continuous cardiac monitoring to assess for any arrhythmias or changes in the electrocardiogram. Consider platelet transfusion\u00a0under the guidance of a hematologist in cases of severe bleeding or refractory thrombocytopenia to restore platelet function and aid in clot formation. Consult\u00a0a toxicologist in severe cases for assistance.", "contents": "Cangrelor -- Toxicity -- Managing Overdose. Managing cangrelor overdose involves providing supportive care and closely monitoring the patient's condition as no specific antidote is available for the drug. Stop the cangrelor infusion immediately and seek assistance from a rapid response team. [37] Monitor the patient's vital signs, including blood pressure, heart rate, and oxygen saturation. Perform continuous cardiac monitoring to assess for any arrhythmias or changes in the electrocardiogram. Consider platelet transfusion\u00a0under the guidance of a hematologist in cases of severe bleeding or refractory thrombocytopenia to restore platelet function and aid in clot formation. Consult\u00a0a toxicologist in severe cases for assistance."}
{"id": "article-156148_61", "title": "Cangrelor -- Enhancing Healthcare Team Outcomes", "content": "Interdisciplinary collaboration and effective communication among these healthcare professionals are essential to optimize patient outcomes and ensure the safe use of cangrelor. By working together, they can provide comprehensive care, monitor for potential adverse events, and adjust the treatment plan to achieve the best possible results for the patient.\u00a0When cangrelor is administered to a patient, several disciplines may be involved in\u00a0treating the patient\u00a0and managing their condition.", "contents": "Cangrelor -- Enhancing Healthcare Team Outcomes. Interdisciplinary collaboration and effective communication among these healthcare professionals are essential to optimize patient outcomes and ensure the safe use of cangrelor. By working together, they can provide comprehensive care, monitor for potential adverse events, and adjust the treatment plan to achieve the best possible results for the patient.\u00a0When cangrelor is administered to a patient, several disciplines may be involved in\u00a0treating the patient\u00a0and managing their condition."}
{"id": "article-156148_62", "title": "Cangrelor -- Enhancing Healthcare Team Outcomes", "content": "The cardiologist plays a central role in the administration of cangrelor, as they are responsible for determining the appropriate indication, dosage, and duration of therapy. In addition, the cardiology\u00a0team\u00a0monitors the patient's cardiovascular status, assesses the need for antiplatelet therapy, and evaluates the response to treatment.", "contents": "Cangrelor -- Enhancing Healthcare Team Outcomes. The cardiologist plays a central role in the administration of cangrelor, as they are responsible for determining the appropriate indication, dosage, and duration of therapy. In addition, the cardiology\u00a0team\u00a0monitors the patient's cardiovascular status, assesses the need for antiplatelet therapy, and evaluates the response to treatment."}
{"id": "article-156148_63", "title": "Cangrelor -- Enhancing Healthcare Team Outcomes", "content": "Clinical\u00a0pharmacists play a crucial role in ensuring the safe and effective use of cangrelor. They provide medication reconciliation, assess potential drug interactions, recommend appropriate dosing adjustments in patients with renal or hepatic impairment, and educate patients on the medication.\u00a0Cardiothoracic surgery is required for off-label uses. A hematologist consultation may be necessary for severe bleeding. Pathologist provides valuable input regarding the appropriate laboratory monitoring.\u00a0Nursing should\u00a0monitor the patient and inform the team regarding any adverse event.", "contents": "Cangrelor -- Enhancing Healthcare Team Outcomes. Clinical\u00a0pharmacists play a crucial role in ensuring the safe and effective use of cangrelor. They provide medication reconciliation, assess potential drug interactions, recommend appropriate dosing adjustments in patients with renal or hepatic impairment, and educate patients on the medication.\u00a0Cardiothoracic surgery is required for off-label uses. A hematologist consultation may be necessary for severe bleeding. Pathologist provides valuable input regarding the appropriate laboratory monitoring.\u00a0Nursing should\u00a0monitor the patient and inform the team regarding any adverse event."}
{"id": "article-156148_64", "title": "Cangrelor -- Enhancing Healthcare Team Outcomes", "content": "According to the CAMEO registry (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes), considerable variation in the utilization of cangrelor is evident across different hospitals, with only 27% of patients receiving cangrelor and transitioning to an oral P2Y 12 inhibitor in adherence to the clinical trial and FDA label.", "contents": "Cangrelor -- Enhancing Healthcare Team Outcomes. According to the CAMEO registry (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes), considerable variation in the utilization of cangrelor is evident across different hospitals, with only 27% of patients receiving cangrelor and transitioning to an oral P2Y 12 inhibitor in adherence to the clinical trial and FDA label."}
{"id": "article-156148_65", "title": "Cangrelor -- Enhancing Healthcare Team Outcomes", "content": "Additionally, over one-third of patients are administered a cangrelor infusion for a duration shorter than what is recommended by the FDA (<2 h). These results have important clinical implications, emphasizing the need for improvement in P2Y 12 inhibitor transition for individuals undergoing\u00a0PCI after experiencing an MI. The strategy suggested is\u00a0improving the knowledge and understanding of\u00a0clinicians\u00a0and pharmacists to facilitate the appropriate utilization and smooth transition of cangrelor to an oral P2Y 12 inhibitor. [38]", "contents": "Cangrelor -- Enhancing Healthcare Team Outcomes. Additionally, over one-third of patients are administered a cangrelor infusion for a duration shorter than what is recommended by the FDA (<2 h). These results have important clinical implications, emphasizing the need for improvement in P2Y 12 inhibitor transition for individuals undergoing\u00a0PCI after experiencing an MI. The strategy suggested is\u00a0improving the knowledge and understanding of\u00a0clinicians\u00a0and pharmacists to facilitate the appropriate utilization and smooth transition of cangrelor to an oral P2Y 12 inhibitor. [38]"}
{"id": "article-156148_66", "title": "Cangrelor -- Enhancing Healthcare Team Outcomes", "content": "Consequently, an interprofessional team approach utilizing open communication and shared decision-making\u00a0among clinicians, including specialists, pharmacists, and toxicologists, is essential to improve patient outcomes related to cangrelor therapy.", "contents": "Cangrelor -- Enhancing Healthcare Team Outcomes. Consequently, an interprofessional team approach utilizing open communication and shared decision-making\u00a0among clinicians, including specialists, pharmacists, and toxicologists, is essential to improve patient outcomes related to cangrelor therapy."}
{"id": "article-156148_67", "title": "Cangrelor -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Cangrelor -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}